@krispi
Thank you for your excellent post.
I agree with the medical aspects.
I disagree with the 1 in 250 chance valuation calculation. That would be correct if no more expenditure was required to reach drug approval stage. But there's a lot more expenditure required to reach drug approval stage. The market is taking that into account, although maybe inaccurately.
- Forums
- ASX - By Stock
- XanaHES and its implications for Actinogen
@krispiThank you for your excellent post.I agree with the...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
6.5¢ |
Change
0.003(4.84%) |
Mkt cap ! $174.3M |
Open | High | Low | Value | Volume |
6.1¢ | 6.6¢ | 6.1¢ | $397.2K | 6.268M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 679730 | 6.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 560502 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 679730 | 0.063 |
5 | 715406 | 0.062 |
4 | 712880 | 0.061 |
5 | 2116854 | 0.060 |
4 | 621600 | 0.058 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 460502 | 4 |
0.066 | 416583 | 5 |
0.067 | 227867 | 2 |
0.068 | 207426 | 3 |
0.069 | 330007 | 4 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |